Reuters Events' Cell & Gene Therapy USA

Reuters Events 2 November 2020, Virtual Event, USA.
Join 2500+ gene and cell therapy leaders for this (free to attend) conference brough to you by Reuters Events.

The race to commercialize cell & gene therapies (CGT) is heating up. Almost all of top 20 pharma have dedicated strategies, while US policy makers and the FDA are facilitating innovation and accelerating pathways to market.

With so few treatments on the market to benchmark against, and a relatively unknown understanding of the long-term patient journey, the industry knows it has huge challenges to overcome.

It's not good enough to sell patients and physicians on the dream. We must forge the way alongside government and payers to build new reimbursement models, and scale manufacturing with the optimal patient journey at the centre. All of this while continuing to identify new patient populations to ensure long-term commercial success.

Reuters Events' Cell & Gene Therapy Conference will bring together every key stakeholder to define commercialization approaches and get your solution to patients faster.

Exceptional online networking opportunities

You won't find an online cell and gene commercialization networking experience elsewhere. Reuters Events Pharma Cell & Gene Therapy USA 2020 is the only place to connect with commercialization leaders, patient experience experts, pricing and policy advisors, engagement and education front-runners.

Here's how:

  • Connect 1-on-1 with fellow attendees: Over several weeks, you'll have access to our online messaging platform, allowing you to connect with like-minded pharma leaders and set up a virtual coffee or formal meeting in your own time.
  • Interactivity: With 15+ interactive sessions including virtual workshops, live Q&As and panels, make your voice heard as a thought leader via the speaker question and messaging functions.

For further information and to register, please visit:
https://www.reutersevents.com/events/cellandgene

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...